Both L0 and L1 cells were efficiently transduced by all three vectors; however, HAdV-C5.survivin was able to transduce these cells more efficiently than the HAdV-C5.hTERT and HAdV-C5.hTERT/survivin fusion, suggesting that survivin may be the most promising tumour-specific promoter for future therapeutic applications in GBM both in terms of the quantity and the selectivity of transgene expression in GBM cell lines. The gene discussed is BIRC5; the disease is neoplasm.